Fluid secretion in bowel

Fluid secretion in bowel refers to the complex physiological process whereby water and electrolytes are actively transported from the intestinal mucosa into the lumen. This mechanism is primarily driven by the active secretion of chloride (Cl-) and bicarbonate (HCO3-) ions across the apical membrane of enterocytes, facilitated by channels such as the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Calcium-activated Chloride Channels (CaCC) [1, 2, 5]. The resulting osmotic gradient draws water into the lumen, which is essential for maintaining stool hydration, lubricating the intestinal wall, and facilitating waste transit [1, 8]. Dysregulation of this process is a hallmark of several gastrointestinal disorders, ranging from chronic constipation and Irritable Bowel Syndrome (IBS) to life-threatening secretory diarrheas caused by pathogens like Vibrio cholerae. Pharmacological intervention focuses on the molecular targets governing this flux; secretagogues like linaclotide are used to treat constipation by increasing fluid volume, while antisecretory agents such as crofelemer are utilized to reduce excessive fluid loss in diarrheal conditions [2, 3, 9]. As a therapeutic focus, fluid secretion represents a functional endpoint rather than a single molecular entity, involving a coordinated network of transporters, ion channels, and signaling receptors [1, 5].

Other names

Intestinal fluid secretionIntestinal secretionColonic fluid secretionGastrointestinal fluid secretionEnteric secretion

Drugs modulate this process by either activating or inhibiting specific molecular drivers. Secretagogues like linaclotide and plecanatide act as agonists for Guanylate Cyclase-C (GC-C), increasing intracellular cGMP to open the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) chloride channel [3, 7]. Lubiprostone activates ClC-2 chloride channels, while tenapanor inhibits the Sodium/Hydrogen Exchanger 3 (NHE3) to prevent sodium and water absorption [3, 8]. Conversely, crofelemer and octreotide inhibit secretion by blocking chloride channels or reducing pro-secretory peptide levels, respectively [2, 10].